American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. It serves providers, payers, and the government, as well as the higher education sector. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.…
American Well (AMWL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
American Well (NYSE: AMWL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 562 employees.
The shares were at 10.75 USD on 20 November 2026, up 155.3% over 52 weeks. Its 52-week range is 3.710 USD to 15.15 USD: the price is 29.0% below the high and 189.8% above the low.
Its market capitalisation is 185.12M USD.
American Well reports return on equity of -40.6%, an operating margin of -24.9% and revenue down 13.0% year over year.
It holds more cash than debt, a net cash position of 178.78M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 13.60 USD is 26.5% above the current price. The next earnings report is expected on 11 February 2027.